Figure 3 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

ESR1m ctDNA dynamics for each CDK4/6i + camizestrant combination. (Top) waterfall plot showing percentage change in ESR1m summed VAF at C2D1 compared with C1D1 in each evaluable patient. (Middle) vector plot showing absolute ESR1m ctDNA change. The dots indicate the summed VAF observed in the C1D1 sample (magenta) and the C2D1 sample (black). (Bottom) tile plot of ESR1m identified in each patient by ctDNA. ESR1m was defined as a mutation that gives rise to one of the following amino acid changes: E380Q, V422del, S463P, L536H/P/R, Y537C/D/N/S, or D538G. C1D1, cycle 1, day 1; C2D1, cycle 2, day 1; nd, not detected; sVAF, summed variant allele frequency; VAF, variant allele frequency.